Search clinical trials for: Secukinumab 150mg

Total 2003 results

LG Chem

Unknown

A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2
Henry M. Jackson Foundation for the Advancement...
Gilead Sciences

Withdrawn

Antiretroviral Therapy for Acute HIV Infection

HIV Infections

Uganda
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

ZL-82 Double-blind Clinical Trial

Healthy Person

China
Novartis Pharmaceuticals

Completed

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE)

Hidradenitis Suppurativa

United States, Spain, Russian Federation, Taiwan, Germany, France, United Kingdom, Korea, Republic of, Japan, Australia, Switzerland, Austria, Italy, Sweden, India, Israel, Mexico, Philippines, Portugal, Turkey, Greece, Hungary, Bul... and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)

Non-radiographic Spondyloarthritis

United States, Spain, Belgium, Hungary, Turkey, Netherlands, Austria, Israel, Sweden, Switzerland, Germany, Korea, Republic of, Australia, Russian Federation, Italy, Portugal, United Kingdom, Bulgaria, France, Czechia, Poland, Japan, Mexi... and more
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals

Terminated

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Necrobiosis Lipoidica Diabeticorum

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE)

Hidradenitis Suppurativa

Belgium, Italy, United Kingdom, United States, Hungary, Malaysia, Germany, Netherlands, France, Israel, Lebanon, Singapore, Spain, Bulgaria, Lithuania, Argentina, Turkey, Guatemala, Switzerland, Vietnam, Philippines, Croatia, India, S... and more
Novartis Pharmaceuticals

Withdrawn

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). (CAIN457X12301)

Active Peripheral Spondyloarthritis (pSpA)
Massachusetts General Hospital
Novartis

Withdrawn

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

United States
Icahn School of Medicine at Mount Sinai
Novartis

Terminated

A Study of Secukinumab for the Treatment of Alopecia Areata

Alopecia Areata

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (PROSE)

Plaque Psoriasis

Germany, United Kingdom, Belgium, Czechia, Estonia, Italy, France, Israel, Spain, Bulgaria, Lithuania, Portugal, Poland, Romania, Latvia, Greece, Slovakia
Diamant Thaci
Novartis

Completed

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients (BIOMARKER)

Psoriasis Vulgaris

Germany
Tanja Todberg, MD

Unknown

Anti-IL-17 a New Treatment for Contact Dermatititis

Allergic Contact Dermatitits

Denmark
Novartis Pharmaceuticals

Terminated

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Novartis Pharmaceuticals

Terminated

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, United Kingdom, Germany, Hungary, Russian Federation, Taiwan, Belgium, Netherlands, Japan, Austria, Finland, Slovakia, Czechia, Canada, Iceland, Poland
University of Pennsylvania
Novartis

Recruiting

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Psoriasis

United States
Shire

Terminated

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

Alzheimer's Disease

Brazil, South Africa, Chile, Hungary, Bulgaria, Czechia, Germany, Japan, Mexico, Poland, Russian Federation, Slovakia
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy (UnchAIN)

Tendinopathy

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Ankylosing Spondyloarthritis

United Kingdom, Korea, Republic of, China, Czechia
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

Chronic Plaque Psoriasis
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Novartis Pharmaceuticals

Active, not recruiting

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

Argentina, Canada, Guatemala, Mexico, Brazil, Costa Rica, Dominican Republic, Panama
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Novartis Pharmaceuticals

Recruiting

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (REPLENISH-EXT)

Polymyalgia Rheumatica

Australia
Chong Kun Dang Pharmaceutical

Completed

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers

Diabetes Mellitus, Type II

Korea, Republic of
Nottingham University Hospitals NHS Trust
University of Nottingham; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis... and other collaborators

Completed

Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 (GIFT-CF2)

Cystic Fibrosis

United Kingdom
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Novartis Pharmaceuticals

Completed

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

Ankylosing Spondylitis

United States
Novartis Pharmaceuticals

Completed

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (METABOLYX)

Psoriasis | Metabolic Syndrome

Germany
Novartis Pharmaceuticals

Completed

Extension in AS: Sustainability of Benefits, Safety and Tolerability (MEASURE 1 ext)

Spondylitis, Ankylosing

Belgium, Germany, Netherlands, France, United States, Bulgaria, Italy, Mexico, Russian Federation, Peru, United Kingdom, Turkey, Canada, Taiwan
Novartis Pharmaceuticals

Completed

Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg (OFM ISF)

Healthy | Psoriasis

Austria
Novartis Pharmaceuticals

Completed

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)

Psoriasis

France
Novartis Pharmaceuticals

Completed

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Psoriasis, Plaque-type Psoriasis

United States
Novartis Pharmaceuticals

Completed

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)

Spondylitis, Ankylosing

Germany, Spain, United Kingdom, United States, Belgium, Greece, Portugal, Russian Federation, Czechia, Mexico
MedImmune LLC

Completed

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Denmark, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, United Kingdom
King's College Hospital NHS Trust
Merck Sharp & Dohme LLC; Hepatitis C Trust

Terminated

ATTIC - Access To Treat in the Community (ATTIC)

Hepatitis C, Chronic

United Kingdom
Novartis Pharmaceuticals

Completed

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

Belgium, Spain, Russian Federation, Germany, United States, Czechia, Peru, Poland, Estonia
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

Non-radiographic Axial Spondyloarthritis

China
Novartis Pharmaceuticals

Withdrawn

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (INTERCEPT)

Psoriasis
Eurofarma Laboratorios S.A.

Not yet recruiting

A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (UNLIMITED)

Obesity | Overweight

Brazil
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE 1)

Ankylosing Spondylitis

Germany, Belgium, Netherlands, France, United States, Bulgaria, Italy, Russian Federation, Peru, United Kingdom, Canada, Mexico, Taiwan, Turkey
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia

Search clinical trials for: Secukinumab 150mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations